Antonia Lloyd-Lavery

9PUBLICATIONS
23CO-AUTHORS
Infant and child healthApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Epidemiological modellingAllergyDermatology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 05, 2026
The association between COVID-19 vaccines and bullous pemphigoid risk: A UK population-based study.

|Aug 13, 2025
Successful treatment of refractory chilblain lupus erythematosus with bosentan.

Shannon Gunawardana, Alexander J Clarke, Antonia Lloyd-Lavery

|Jun 27, 2025
Incidence rates of bullous pemphigoid, herpes zoster and urticaria following the start of the COVID-19 vaccination programme in the UK: a population-based cohort study.

Mikolaj Swiderski, Sarah Lewis, Yana Vinogradova

|Sep 02, 2023
Nemolizumab to target the itch-scratch cycle in paediatric atopic dermatitis.

Antonia Lloyd-Lavery

|May 18, 2023
The top 10 research priorities for the treatment of bullous pemphigoid, mucous membrane pemphigoid and pemphigus vulgaris in the UK: results of a James Lind Alliance Priority Setting Partnership.

Karen E Harman, Jag Barha, Jo R Chalmers

|May 13, 2023
Further evidence for the long-term safety of guselkumab.

Antonia Lloyd-Lavery

Pageof 2

Frequent Collaborators

2 joint publications

Zenas Z N Yiu

2 joint publications

Matthew J Ridd

1 joint publications

M K Shephard

1 joint publications

Yi-Ling Chen